Komori
M&A and Subsidiary Changes7915Nissha Co.,Ltd.Information and Communications, Services and Others

Notice Concerning a Change in a Consolidated Subsidiary (Specified Subsidiary) (Share Transfer)

NISSHA and its consolidated subsidiary Nissha Vietnam plan to transfer their combined 60% interest in USM to VÕ XUÂN BỘI LÂM, a director of USM. The transfer of 50% is scheduled for mid-September 2026, and the remaining 10% is scheduled to be transferred between mid-September 2027 and mid-September 2028. USM is expected to be excluded from the scope of consolidation.

Worth reading
47Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
60
Ownership interest in USM shares (%)
Wording
Conditional
How definitive the wording is.

This transaction

Share Transfers
CounterpartyVÕ XUÂN BỘI LÂM
Disclosing companyNissha Co.,Ltd.
USM HEALTHCARE MEDICAL DEVICES FACTORY JOINT STOCK COMPANYSubject of this transactionNumber of shares acquired Number of shares transferred: 16,960,877 shares (number of voting rights: 16,960,877)Voting rights ownership percentage Before 59.99% (held by the Company; Nissha Vietnam Co., Ltd. holds 0.01%) (after not disclosed)
TimelineThe spacing between the points is proportional to the actual number of days.
Target company

Manufacture and sale of medical devices

Location Saigon Hi-tech Park, Long Thanh My Ward, HCMC (Vietnam)Share capital VND 282,681,280,000Date of incorporation October 2012
Net SalesVND 416,587 million (fiscal year ended December 2025)
Net income for the current fiscal yearVND 28,030 million (fiscal year ended December 2025)
Net assetsVND 831,615 million (fiscal year ended December 2025)
Consideration and expenses
Acquisition priceNot disclosed due to the confidentiality obligations between the parties.
Amount of extraordinary income (loss)The Company expects to recognize a gain or loss on the sale of shares in an affiliate in its standalone and consolidated financial statements for the fiscal year ending December 2026. The amount is currently under review.
Impact on Business Performance

The impact on the consolidated full-year earnings forecast for the fiscal year ending December 2026 is currently under review. The Company will provide prompt disclosure once the impact is determined.

This transaction
ItemDetails
Transaction nameShare Transfers
Counterparty nameVÕ XUÂN BỘI LÂM
Name of the Subject CompanyUSM HEALTHCARE MEDICAL DEVICES FACTORY JOINT STOCK COMPANY
Business Description of the Subject CompanyManufacture and sale of medical devices
Location of the Subject CompanySaigon Hi-tech Park, Long Thanh My Ward, HCMC (Vietnam)
Capital Stock of the Subject CompanyVND 282,681,280,000
Date of Establishment of the Subject CompanyOctober 2012
Net Sales of the Subject CompanyVND 416,587 million (fiscal year ended December 2025)
Net Income of the Subject CompanyVND 28,030 million (fiscal year ended December 2025)
Net Assets of the Subject CompanyVND 831,615 million (fiscal year ended December 2025)
Acquisition priceNot disclosed due to the confidentiality obligations between the parties.
Number of shares acquiredNumber of shares transferred: 16,960,877 shares (number of voting rights: 16,960,877)
Voting rights ownership percentageBefore 59.99% (held by the Company; Nissha Vietnam Co., Ltd. holds 0.01%) (after not disclosed)
Amount of extraordinary income (loss)The Company expects to recognize a gain or loss on the sale of shares in an affiliate in its standalone and consolidated financial statements for the fiscal year ending December 2026. The amount is currently under review.
Impact on Business PerformanceThe impact on the consolidated full-year earnings forecast for the fiscal year ending December 2026 is currently under review. The Company will provide prompt disclosure once the impact is determined.
Date of board resolution4 September 2026
Contract Date4 September 2026
Execution Date / Effective DateMid-September 2026 (50% of USM shares) (scheduled); mid-September 2027 to mid-September 2028 (10% of USM shares) (scheduled)
Items this document does not state (14)
Operating Profit of the Subject CompanyExpenses other than the acquisition priceType of ConsiderationMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodFunding arrangementsGoodwill amountValuation methodologyIndependent valuation institutionSpecial CommitteeConditions Precedent to ExecutionManagement structure after acquisition

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Inappropriate accounting practices centered on circular transactions were identified at USM before its acquisition. After examining the feasibility of realizing the benefits of the acquisition and its potential impact on USM's future corporate value, the Company determined that it would be difficult to preserve and enhance the corporate value of the Group.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Concerning a Change in a Consolidated Subsidiary (Specified Subsidiary) (Share Transfer) | Nissha Co.,Ltd. (7915) timely disclosure | Komori